Patents Examined by Rachael Bredefeld
-
Patent number: 9993463Abstract: The present invention is related to a compound of formula (I) a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.Type: GrantFiled: December 10, 2013Date of Patent: June 12, 2018Assignee: Centogene AGInventors: Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Arndt Rolfs, Anahit Pews-Davtyan
-
Patent number: 9956288Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.Type: GrantFiled: October 19, 2016Date of Patent: May 1, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Stefan Henke, Bernd Kruss, Bernhard Hassel, Hans-Juergen Kroff, Martin A. Folger, Klaus Daneck, Axel Prox
-
Patent number: 9789187Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.Type: GrantFiled: February 8, 2010Date of Patent: October 17, 2017Assignee: Cadila Pharmaceuticals LimitedInventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi
-
Patent number: 9770354Abstract: The present invention relates to an intra-oral device including a carrier that has an outside wall, an inside wall and an occlusal wall connecting the outside wall to the inside wall. The carrier has at least one inset and at least one insert carrying a beneficial agent that is adapted to fit the inset, and the beneficial agent is capable of promoting weight loss. The intra-oral device is positioned in a user's mouth so that the intra-oral device is in contact with the user's cheeks, lips and/or tongue and the beneficial agent passes through the mucosal membrane of the user's mouth.Type: GrantFiled: June 22, 2016Date of Patent: September 26, 2017Assignee: Dynamic Mouth Devices, L.L.C.Inventors: Laura Bardach, James Geduldig, Salvatore Napoli
-
Patent number: 9750245Abstract: The present document describes a method of reducing a microbial presence on at least one part of a subject by topically contacting the subject's part with an antimicrobial formulation comprising: a) at least one antimicrobial isolated or synthetic phenolic compound of natural origin; b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in an aqueous carrier; c) a solvent for dissolving said phenolic compound; and d) a sufficient aqueous carrier quantity to make 100% (w/w).Type: GrantFiled: March 8, 2013Date of Patent: September 5, 2017Assignee: LABORATOIRE M2Inventors: Gaetan Lemire, Ulysse Desranleau Dandurand, Sylvain Quessy, Ann Letellier
-
Patent number: 9744189Abstract: Lithium is regarded as the gold standard comparator and benchmark treatment for mania. One of the problems associated with Lithium is its narrow therapeutic window. Recent attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these potential new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using cocrystallization is currently underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (lithium salicylate and lithium lactate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats.Type: GrantFiled: November 12, 2014Date of Patent: August 29, 2017Assignee: University of South FloridaInventors: Adam J. Smith, R. Douglas Shytle
-
Patent number: 9700623Abstract: The present invention features a pharmaceutical composition used for reducing the damage caused by free radicals, which comprises at least a metal or its ions, at least a drug or an antioxidant that is carrier-protected/modified, and a drug carrier. Said carrier helps to preserve the anti-oxidative activity, and hence, prevents the decrease of the effect of the antioxidant against free radicals produced in the environment or body fluids and prolongs protection, and may be used for reducing damage caused by radiation and adverse effects induced by chemotherapeutic drugs.Type: GrantFiled: November 22, 2012Date of Patent: July 11, 2017Assignee: ORIGINAL BIOMEDICALS CO., LTD.Inventors: Chia-Hung Chen, Chau-Hui Wang, John-Son Lin, Tieh-Hsiung Chiu, Jing-Yi Chen, Pi-Hung Liao, Chia-Chi Su, Wei-Chuan Liao
-
Patent number: 9655966Abstract: A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consiType: GrantFiled: September 25, 2008Date of Patent: May 23, 2017Inventors: Kedar N. Prasad, Gerald M. Haase, William C. Cole
-
Patent number: 9655924Abstract: Disclosed herein are compositions for treatment of ear infection (such as bacterial and/or yeast infection) in human or veterinary subjects. In some embodiments the compositions include silver microparticles, for example about 0.1% silver microparticles, about 0.2% silver microparticles, or about 0.4% silver microparticles. Also disclosed are methods for treating ear infection in a subject utilizing one or more of the disclosed compositions, for example sequential application of compositions including about 0.1% silver microparticles, about 0.2% silver microparticles, and about 0.4% silver microparticles to the ear canal of the subject. In some examples, one or more of the disclosed compositions are provided in a kit.Type: GrantFiled: April 8, 2015Date of Patent: May 23, 2017Assignee: BioMedtrix, LLCInventors: Christopher G. Sidebotham, Alan Mundell
-
Patent number: 9596850Abstract: Disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant having a cloud point in the range of about 30° C. to 50° C. Also disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant, wherein the second surfactant is a quaternary ammonium compound. A process for preparing the compositions of the invention is also disclosed. The compositions of the invention are low or substantially non-foaming under high pressure, high temperature conditions, thus allowing maximum benefit from the new, more reliable, generation of automated endoscope reprocessing machines.Type: GrantFiled: March 28, 2008Date of Patent: March 21, 2017Assignee: #hiteley Corporation PTY. LTD.Inventors: Reginald Keith Whiteley, Marilyn Emily Karaman, Gregory Stuart Whiteley